Literature DB >> 32276200

Comparison of prevalence rates of restless legs syndrome, self-assessed risks of obstructive sleep apnea, and daytime sleepiness among patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

Vahid Shaygannejad1, Dena Sadeghi Bahmani2, Parisa Soleimani3, Omid Mirmosayyeb4, Mehran Barzegar3, Babak Amra5, Serge Brand6.   

Abstract

BACKGROUND: Prevalence rates for restless legs syndrome (RLS) and risk of Obstructive Sleep Apnea (OSA) in individuals with Neuromyelitis Optica Spectrum Disorder (NMOSD) and Clinically Isolated Syndrome (CIS) are unknown. The aims of the present study were to assess symptoms of RLS and self-assessed risks of OSA in individuals with NMOSD and CIS, to compare these prevalence rates with those of persons with multiple sclerosis (MS), and to associate RLS and OSA with expanded disability status scale (EDSS) scores, daytime sleepiness, fatigue, paresthesia, and medication.
METHODS: A total of 495 individuals (mean age = 34.92 years, 84.9% females) were assessed. Of these, 24 had NMOSD, 112 had CIS and 359 had MS. Trained neurologists ascertained individuals' neurological diagnoses, assessed their EDSS scores, and conducted a clinical interview to assess RLS. Additionally, participants completed questionnaires covering sociodemographic information, risks of snoring and OSA, daytime sleepiness, fatigue, paresthesia and medication.
RESULTS: Prevalence rates of RLS were 45.8% in NMOSD, 41.1% in CIS, and 28.7% in MS. Prevalence rates of self-assessed risks of OSA were 8.3% in NMOSD, 7.7% in CIS, and 7.8% in MS; these rates were not significantly different. Across the entire sample and within the diagnostic groups, RLS and OSA scores were unrelated to EDSS, daytime sleepiness, fatigue or medication.
CONCLUSIONS: Individuals with NMOSD, CIS and MS have high prevalence rates for RLS and self-assessed risks of obstructive sleep apnea syndrome (OSAS), which are unrelated to EDSS, daytime sleepiness, fatigue, paresthesia, or medication. Sleep issues should be monitored during routine check-ups for individuals with NMOSD and CIS.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Clinically isolated syndrome; Daytime sleepiness; Multiple sclerosis; Neuromyelitis optica spectrum disorder; Obstructive sleep apnea; Restless legs syndrome

Mesh:

Year:  2019        PMID: 32276200     DOI: 10.1016/j.sleep.2019.11.1266

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  5 in total

1.  Sleep Quality in Neuromyelitis Optica Spectrum Disorder: A Systematic Review.

Authors:  Arshia Eshtiaghi; David Eapen-John; Kirill Zaslavsky; Reza Vosoughi; Brian J Murray; Edward Margolin
Journal:  Int J MS Care       Date:  2021-08-18

Review 2.  The prevalence of restless legs syndrome (RLS) in patients with multiple sclerosis (MS): a systematic review and meta-analysis-an update.

Authors:  Alireza Zali; Mahsa Motavaf; Saeid Safari; Narges Ebrahimi; Mahsa Ghajarzadeh; Reza Jalili Khoshnood; Omid Mirmosayyeb
Journal:  Neurol Sci       Date:  2022-09-05       Impact factor: 3.830

3.  Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Haojie Xie; Yingzhe Shao; Juan Du; Yajun Song; Yanfei Li; Ranran Duan; Yaobing Yao; Zhe Gong; Junfang Teng; Yanjie Jia
Journal:  J Neurol       Date:  2021-08-12       Impact factor: 4.849

4.  Compared to Individuals with Mild to Moderate Obstructive Sleep Apnea (OSA), Individuals with Severe OSA Had Higher BMI and Respiratory-Disturbance Scores.

Authors:  Leeba Rezaie; Soroush Maazinezhad; Donald J Fogelberg; Habibolah Khazaie; Dena Sadeghi-Bahmani; Serge Brand
Journal:  Life (Basel)       Date:  2021-04-21

Review 5.  Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

Authors:  Andrea Salazar-Camelo; Naveen George; Hesham Abboud; Sarah M Planchon; Marcelo Matiello; Maureen A Mealy; Andrew Goodman
Journal:  J Neurol       Date:  2021-09-05       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.